Data availability statement:
Research data are not shared due to confidentiality.
References
1. Rawal N. Current issues in postoperative pain management. Eur J Anaesthesiol . 2016;33(3):160-171. doi:10.1097/EJA.0000000000000366.
2. Heppolette CAA, Brunnen D, Bampoe S and Odor PM. Clinical Pharmacokinetics and Pharmacodynamics of Levobupivacaine. Clin Pharmacokinet . 2020;59(6):715-745. doi:10.1007/s40262-020-00868-0.
3. Balocco AL, Van Zundert PGE, Gan SS, Gan TJ and Hadzic A. Extended release bupivacaine formulations for postoperative analgesia: an update.Curr Opin Anaesthesiol . 2018;31(5):636-642. doi:10.1097/ACO.0000000000000648.
4. Hussain N, Brull R, Sheehy B, et al. Perineural Liposomal Bupivacaine Is Not Superior to Nonliposomal Bupivacaine for Peripheral Nerve Block Analgesia. Anesthesiology . 2021;134(2):147-164. doi:10.1097/ALN.0000000000003651.
5. Ilfeld BM, Eisenach JC and Gabriel RA. Clinical Effectiveness of Liposomal Bupivacaine Administered by Infiltration or Peripheral Nerve Block to Treat Postoperative Pain. Anesthesiology . 2021;134(2):283-344. doi:10.1097/ALN.0000000000003630.
6. Xu J, Wong DH, Byrne JD, et al. Future of the particle replication in nonwetting templates (PRINT) technology. Angew Chem Int Ed Engl . 2013;52(26):6580-6589. doi:10.1002/anie.201209145.
7. Doherty MM, Hughes PJ, Charman SA, et al. Biphasic drug absorption from the epidural space of the dog may limit the utility of a slow release medium molecular weight hyaluronic acid-lidocaine ionic complex formulation. Anesth Analg . 1996;83(6):1244-1250. doi:10.1097/00000539-199612000-00020.
8. Viscusi ER, Candiotti KA, Onel E, Morren M and Ludbrook GL. The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers.Reg Anesth Pain Med . 2012;37(6):616-622. doi:10.1097/AAP.0b013e318269d29e.
9. Hu D, Onel E, Singla N, Kramer WG and Hadzic A. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site. Clin Drug Investig . 2013;33(2):109-115. doi:10.1007/s40261-012-0043-z.
10. Simon MJ, Veering BT, Stienstra R, et al. The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. Eur J Anaesthesiol . 2004;21(6):460-470. doi:10.1017/s0265021504006088.
11. Olofsen E, Burm AG, Simon MJ, et al. Population pharmacokinetic-pharmacodynamic modeling of epidural anesthesia.Anesthesiology . 2008;109(4):664-674. doi:10.1097/01.anes.0000334302.50559.c9.
12. Schnider TW, Minto CF, Bruckert H and Mandema JW. Population pharmacodynamic modeling and covariate detection for central neural blockade. Anesthesiology . 1996;85(3):502-512. doi:10.1097/00000542-199609000-00009.
13. Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U and Lykkesfeldt J. BCPT 2023 policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol . 2023;133(4):391-396. doi:10.1111/bcpt.13944.
14. Pedersen JL, Lillesø J, Hammer NA, et al. Bupivacaine in microcapsules prolongs analgesia after subcutaneous infiltration in humans: a dose-finding study. Anesthesia and Analgesia . 2004;99(3):912-918.
15. Sheiner LB, Rosenberg B and Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm . 1977;5(5):445-479. doi:10.1007/BF01061728.
16. Duffull SB, Wright DF and Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.Br J Clin Pharmacol . 2011;71(6):807-814. doi:10.1111/j.1365-2125.2010.03891.x.
17. Mould DR and Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol . 2012;1(e6. doi:10.1038/psp.2012.4.
18. Mould DR and Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol . 2013;2(e38. doi:10.1038/psp.2013.14.
19. Upton RN and Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst Pharmacol . 2014;3(e88. doi:10.1038/psp.2013.71.
20. Beal SL. Ways to Fit a PK Model with Some Data Below the Quantification Limit. J Pharmacokinet Pharmacodyn . 2001;28(5):481-504.
Table 1. Population parameter values for the intermediate (int.) population pharmacokinetic model, the population pharmacodynamic model, and the final population pharmacokinetic-pharmacodynamic model for bupivacaine. Inter-individual variability (IIV) and shrinkage are shown for the final model.